BiotechTube
Tagomics

Tagomics

Cambridge, United Kingdom
tagomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Tagomics is a private, pre-revenue diagnostics company developing a proprietary multiomic profiling platform for disease detection and diagnosis. Based in Cambridge, UK, the company leverages epigenetic, genetic, and fragmentomic data combined with machine learning to identify biomarkers, with an initial focus on colorectal cancer. Key recent developments include an £860k Innovate UK grant and a co-marketing agreement with Agilent, positioning it to commercialize a unified workflow for comprehensive genomic profiling.

Oncology

Technology Platform

Proprietary multiomic platform integrating genetic, epigenetic, and fragmentomic data analysis with advanced bioinformatics and machine learning to identify disease biomarkers from low-input, sample-agnostic sources.

Opportunities

The growing demand for early, accurate, and non-invasive disease diagnostics, particularly in oncology, presents a massive market.
The partnership with Agilent provides a powerful channel for commercialization and validation of its unified workflow.
The platform's flexible, multiomic design allows for expansion into numerous other disease areas beyond its initial colorectal cancer focus.

Risk Factors

The company faces significant technical risk in clinically validating its multiomic signatures and demonstrating superior utility over existing diagnostics.
As a pre-revenue startup in a crowded, capital-intensive field, it is dependent on securing future funding to reach commercialization.
Success also hinges on effectively executing its partnership with the much larger Agilent.

Competitive Landscape

Tagomics operates in the highly competitive multiomic and liquid biopsy diagnostics space, competing against large public companies (e.g., Guardant Health, Exact Sciences) and well-funded startups. Its differentiation lies in the specific integration of epigenetic and fragmentomic data with genomics, and its strategy to provide a unified workflow through a partnership with a major player like Agilent.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →